Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of Leonurine in the Preparation of Retinal Optic Nerve Protective Drugs

A technology of leonurine and retina, which is applied to the preparation of drugs for the treatment of retinal vascular diseases, optic nerve inflammation and degenerative diseases, and optic nerve protective drugs. In the field of retina preparation, leonurine can solve the problems of treating eye diseases that have not yet been seen.

Active Publication Date: 2019-12-03
EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] So far, there has been no report on the use of motherurine in the treatment of eye diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Leonurine in the Preparation of Retinal Optic Nerve Protective Drugs
  • Use of Leonurine in the Preparation of Retinal Optic Nerve Protective Drugs
  • Use of Leonurine in the Preparation of Retinal Optic Nerve Protective Drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1: Leonurine improves the survival rate of damaged RGCs

[0045] (1) Animal model establishment

[0046] a. Intraperitoneal injection 1 hour before modeling. The positive control group received 100 mg / kg of Ginkgo biloba extract, three dosage groups of Leonurine component, 7.5 mg / kg, 15 mg / kg, and 30 mg / kg, respectively, and the injury group received the same volume of normal saline;

[0047] b. Intramuscular injection of ketamine (80mg / kg) and xylazine (12mg / kg). After general anesthesia of the animal, the area around the eyes was cleaned and disinfected. Lincomycin eye drops flush the eyes;

[0048] c. Under the ophthalmic operating microscope, anterior chamber perfusion was performed on the injury group, the positive control group and the motherwort group. Use a 4.5mm scalp vein needle connected to a 0.9% normal saline bag to perform anterior chamber puncture, avoid blood vessels at 3 o'clock and 9 o'clock, lift the saline bag to a height of 150 cm from th...

Embodiment 2

[0063] Example 2: Leonurine reduces full-thickness retinal damage after ischemia-reperfusion injury

[0064] (1) each group is processed by the method in embodiment 1;

[0065] (2) Making paraffin sections

[0066] a. Rats were killed on the 7th, 14th, and 21st days after modeling, and the eyeballs were fixed in the eyeball fixation solution for 48 hours and rinsed for 2 hours;

[0067] b. Dehydration: 50% alcohol, 70% alcohol, 85% alcohol, 95% alcohol, 100% alcohol, 100% alcohol for 2 hours each;

[0068] c. Transparent: transfer to 1 / 2 xylene + absolute ethanol for 2 hours, transfer to pure xylene for 1.5 hours, and pure xylene for 1.5 hours;

[0069] d. Wax immersion: place the treated specimen in 1 / 2 powdered paraffin + 1 / 2 xylene, and place it in a 40°C incubator overnight;

[0070] e. Embedding: raise the temperature of the incubator to 60°C, lift and store the wax 3 times, each time for 1-2 hours, pour the material into the mold on the ironing board, and then put it ...

Embodiment 3

[0083] Example 3: Leonurine reduces the apoptosis rate of retinal ganglion cells after ischemia-reperfusion injury

[0084] (1) each group is processed by the method of embodiment 1;

[0085] (2) Frozen section production

[0086] a. On the 1st and 3rd day after modeling respectively, after deeply anesthetizing the rats with chloral hydrate, use 200ml of filtered 4% paraformaldehyde, fix the eyeballs by cardiac perfusion, and soak them in 4% paraformaldehyde Fixed for 2 hours;

[0087] b. Dehydration in 10%, 20%, 30% sucrose successively;

[0088] c. After dehydration, cut off the cornea at 1mm of the limbus, remove the lens and vitreous tissue, absorb the liquid in the eye cup, embed it in the mold with OCT embedding agent, and then place it in a -20°C refrigerator until it is formed. Transfer to -80°C refrigerator and freeze for 1 hour;

[0089] d. Use a cryostat to slice along the sagittal plane of the eyeball, the thickness of the slice is 10 μm, stick it on a slide-pr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of pharmacy, and particularly relates to a use of leonurine in preparing a retina and optic nerve protection drug, in particular to a use in preparing a drug for treating retinal vascular diseases, optic nerve inflammation and degenerative changes. In the use, by virtue of an anterior chamber normal saline perfusion induced retinal ischemia reperfusion injury model experiment, a result shows the leonurine can reduce the apoptosis of the ischemia reperfusion injured RGCs, can increase the survival rate of the RGCs, can alleviate the thinning degree of the ischemia reperfusion injured retina and has an effect for protecting various layers of the retina; and the leonurine can be prepared into a drug for treating the retina injured diseases, the drug can be used for treating the retinal ischemia reperfusion injury, the retinal and optic nerve degenerative diseases, and used for treating the retinal inflammation diseases by adjusting the inflammation reaction of eyes. A new therapeutic drug is provided for clinically treating the eye diseases.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to the new use of leonurine, a monomer component of traditional Chinese medicine, in pharmacy, in particular to the use of leonurine in the preparation of retinal and optic nerve protective drugs, especially in the preparation and treatment of retinal vascular lesions, optic nerve inflammation and Use in degenerative disease medicine. Background technique [0002] Vision is one of the most important functions for the human body to perceive external stimuli. Visual impairment directly affects the quality of life of human beings, and maintaining good vision depends on the transparency and sensitivity of the normal eyeball. At present, in clinical practice, there are relatively complete treatment measures for most of the optical path system lesions that cause visual impairment, such as cataracts and refractive errors. This highlights the fact that neurodegenerative diseases of the optical path sy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/235A61P27/02A61P3/10A61P9/12A61P27/06A61P9/10A61P27/10A61P25/02
Inventor 莫晓芬石碗如朱依谆麦尔哈巴·肖开提顾纪锋荣先芳熊佳伟王鑫
Owner EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com